Comment
doi: 10.1001/jama.2018.21971.
Number Needed to Treat: Conveying the Likelihood of a Therapeutic Effect
Affiliations
- PMID: 30730545
- DOI: 10.1001/jama.2018.21971
Item in Clipboard
Comment
Number Needed to Treat: Conveying the Likelihood of a Therapeutic Effect
JAMA.
.
No abstract available
Comment on
-
Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.JAMA. 2018 Apr 24;319(16):1677-1686. doi: 10.1001/jama.2018.3197. JAMA. 2018. PMID: 29710164 Free PMC article. Clinical Trial.
Similar articles
-
Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.JAMA. 2018 Apr 24;319(16):1677-1686. doi: 10.1001/jama.2018.3197. JAMA. 2018. PMID: 29710164 Free PMC article. Clinical Trial.
-
Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting.JAMA Cardiol. 2016 Nov 1;1(8):921-928. doi: 10.1001/jamacardio.2016.3028. JAMA Cardiol. 2016. PMID: 27653165 Clinical Trial.
-
Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery.Heart. 2016 May 15;102(10):763-9. doi: 10.1136/heartjnl-2015-308691. Epub 2016 Feb 18. Heart. 2016. PMID: 26891756 Clinical Trial.
-
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts.Chest. 1995 Oct;108(4 Suppl):424S-430S. doi: 10.1378/chest.108.4_supplement.424s. Chest. 1995. PMID: 7555193 Review.
-
Radial artery versus saphenous vein conduits for coronary artery bypass surgery: forty years of competition--which conduit offers better patency? A systematic review and meta-analysis.Eur J Cardiothorac Surg. 2011 Jul;40(1):208-20. doi: 10.1016/j.ejcts.2010.11.012. Epub 2010 Dec 16. Eur J Cardiothorac Surg. 2011. PMID: 21167726 Review.
Cited by
-
Benefits and Risks of Antihyperlipidemic Medication in Adults with Different Low-Density Lipoprotein Cholesterol Based on the Number Needed to Treat.Am J Cardiovasc Drugs. 2024 Jul;24(4):557-568. doi: 10.1007/s40256-024-00651-7. Epub 2024 May 23. Am J Cardiovasc Drugs. 2024. PMID: 38782884
-
Public Health Relevance of US EPA Air Quality Index Activity Recommendations.JAMA Netw Open. 2024 Apr 1;7(4):e245292. doi: 10.1001/jamanetworkopen.2024.5292. JAMA Netw Open. 2024. PMID: 38587845 Free PMC article.
-
Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction.Front Pharmacol. 2024 Mar 19;15:1357673. doi: 10.3389/fphar.2024.1357673. eCollection 2024. Front Pharmacol. 2024. PMID: 38567348 Free PMC article.
-
An Energy-Reduced Mediterranean Diet, Physical Activity, and Body Composition: An Interim Subgroup Analysis of the PREDIMED-Plus Randomized Clinical Trial.JAMA Netw Open. 2023 Oct 2;6(10):e2337994. doi: 10.1001/jamanetworkopen.2023.37994. JAMA Netw Open. 2023. PMID: 37851444 Free PMC article. Clinical Trial.
-
Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022.Int J Clin Oncol. 2023 Oct;28(10):1333-1342. doi: 10.1007/s10147-023-02375-1. Epub 2023 Jul 7. Int J Clin Oncol. 2023. PMID: 37418141
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
